drugset / Trial / NCT05687721
Copanlisib and Avelumab as a Maintenance Therapy for Advanced Bladder Cancer
NaSingle-groupOpen-labelTreatment
Summary
Patients with metastatic bladder cancer are usually treated with chemotherapy. If their cancers do not progress after chemotherapy, they can be enrolled into this study and receive a standard-of-care immunotherapy medication named avelumab plus a study drug named copanlisib.
Timeline
- Start
- 2025-06-02
- Primary completion
- 2025-06-02
- Completion
- 2025-06-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Avelumab | Monoclonal antibody | 800 mg | Intravenous |
| Subject | Copanlisib | Small molecule | 60 mg | Intravenous |